Articles

A study presented at the American Academy of Dermatology Virtual Meeting Experience 2021 exhibited new safety and efficacy data for etrasimod as a potential treatment for atopic dermatitis.

Etrasimod Demonstrates New Safety, Efficacy Data for AD in Phase 2 Study

Interim analysis of data from the ECZTEND study evaluating the long-term safety, efficacy, and tolerability of tralokinumab for treatment of atopic dermatitis was presented at AAD VMX 2021.

 Tralokinumab Safe, Effective for Long-Term Treatment of Atopic Dermatitis 

A phase 3 trial found different doses of abrocitinib demonstrated efficacy as a treatment for atopic dermatitis.

Abrocitinib Effective as Flexible Dose for Atopic Dermatitis

Nemolizumab shows positive results according to a recently published post hoc analysis of a phase 2b trial evaluating the drug vs placebo in adult patients with moderate to severe atopic dermatitis (AD). 

Nemolizumab Demonstrates Significant Improvement of AD Symptoms in Phase 2b Trial

The FDA has decided to extend the priority review period for abrocitinib, a JAK1 inhibitor or moderate to severe atopic dermatitis in patients 12 years and older.

FDA Extends Priority Review of Abrocitinib NDA for Atopic Dermatitis

According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.

Pediatric Atopic Dermatitis Linked to Learning Disabilities

Videos

In this video interview, Linda Stein Gold, MD, discusses her recent presentation at the Inaugural SISD regarding using topicals for atopic dermatitis.

Utilizing Topicals for Atopic Dermatitis

Some strains appear to reduce risk in pregnant women and infants.

Probiotic Strains Have Potential to Prevent Pediatric AD

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

Study Confirms Safety Profile of Baricitinib Dose for Atopic Dermatitis

An investigation examines which infants might require screening before peanut introduction.